R Is Hydrogen Or A Lower Saturated Alkyl Of Less Than Seven Carbons Patents (Class 514/629)
  • Patent number: 11766406
    Abstract: Clear bioavailable liquid softgel fill compositions comprising a) at least one analgesic and one or more of decongestants, expectorants, antitussives and/or antihistamines; b) a matrix comprising a pharmaceutically acceptable poly(alkylene glycol) and a pharmaceutically acceptable alkylene glycol; c) a solubilizing agent comprising a pharmaceutically acceptable polymeric solubilizing agent and water are disclosed. Also disclosed are methods for the preparation of such clear fill compositions, and softgel capsules containing the clear bioavailable liquid fill composition.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: September 26, 2023
    Assignee: PuraCap Pharmaceutical LLC
    Inventors: Dahai Guo, Minh Tran, Zhang Julia Zhang
  • Patent number: 11738225
    Abstract: A preparation method for a composite fire extinguishing agent with a cooling function is provided, comprising the steps of conducting refining and hydrophobic treating on heat-absorbing material; and mixing the treated heat-absorbing material and a fire extinguishing agent proportionally to obtain a composite fire extinguishing agent with a cooling function. The present invention enhances the cooling performance of the fire extinguishing agent by adding the heat-absorbing material on the basis of the existing fire extinguishing agent, wherein the heat-absorbing material can absorb the heat released by batteries through phase transition (solid-liquid) heat absorption and decomposition heat absorption.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: August 29, 2023
    Inventors: Xiutao Li, Xiaomeng Zhou
  • Patent number: 11642835
    Abstract: The present disclosure provides methods for freeform extrusion-based additive manufacturing via a robotic arm. In specific aspects, methods are particularly provided for minimally invasive, intracorporeal three-dimensional printing of biocompatible materials. An end effector of a robotic arm includes a sharp member and a reservoir filled with a printing material. The provided method may include piercing a substrate with the sharp member. A bulb or microbolus of material may be extruded beneath the substrate surface to act as an anchor. The end effector may be manipulated to extrude biomaterial along a printing path. Periodically along the printing path, the sharp member is used to pierce the substrate surface create additional respective anchors. In some instances, the method may terminate after extruding material to form a single layer construct. In other instances, the method includes forming one or more layers on top of the initial base layer anchored to the substrate.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: May 9, 2023
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: David J. Hoelzle, Desmond M. D'Souza, Andrej Simeunovic, Ali Asghari Adib
  • Patent number: 11033501
    Abstract: A method for manufacturing a preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent elution properties, preferable hardness and high drug content uniformity, and a premix drug substance of acetaminophen which has improved manufacturability. According to the method in which acetaminophen having a preset particle size is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed and manufacturing efficiency can be elevated. Thus, this method is highly useful for manufacturing an acetaminophen preparation having improved administrability, for example, a reduced size.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: June 15, 2021
    Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Sakamoto, Kunio Komai, Kenji Sakakibara, Hirokazu Banba, Kiyoshi Fukuda
  • Patent number: 11033511
    Abstract: The present invention provides a patch comprising a backing, and an adhesive layer on the backing, wherein the adhesive layer contains at least one drug selected from the group consisting of oxybutynin and a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive base, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0007 to 0.05% by mass based on the total mass of the adhesive layer.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 15, 2021
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Akira Shuto, Takao Kurokawa, Junya Horiuchi, Hidekazu Kuma, Satoshi Amano
  • Patent number: 11008500
    Abstract: Disclosed are alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester used in compositions and methods for inhibiting corrosion. The alkyl lactone-derived hydroxyamide and alkyl lactone-derived hydroxyester are reaction products of an alkyl lactone and an amine, and an alkyl lactone and an alcohol, respectively.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: May 18, 2021
    Assignee: ChampionX USA Inc.
    Inventors: Jeremy Moloney, Jeremy Wayne Bartels, Jeffrey M. Servesko
  • Patent number: 10869854
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: December 22, 2020
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10471039
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: November 12, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10383821
    Abstract: The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: August 20, 2019
    Assignee: RxOMeG Therapeutics LLC
    Inventors: Indu Muni, Naomi Vishnupad
  • Patent number: 10383820
    Abstract: The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: August 20, 2019
    Assignee: RxOMEG Therapeutics LLC
    Inventors: Indu Muni, Naomi Vishnupad
  • Patent number: 10300031
    Abstract: The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and/or a tricyclic antidepressant.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: May 28, 2019
    Assignee: Trinity Laboratories Inc.
    Inventor: Chandra Ulagaraj Singh
  • Patent number: 9987238
    Abstract: Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: June 5, 2018
    Assignee: MALLINCKRODT IP
    Inventors: Mike Allan Royal, James Bradley Breitmeyer
  • Patent number: 9931314
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: April 3, 2018
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9750702
    Abstract: A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: September 5, 2017
    Assignee: INNOPHARMAX, INC.
    Inventors: Weihua Hao, Jongjing Wang, Huiyun Chen
  • Patent number: 9732180
    Abstract: The invention relates to metal complex compounds of the formula Mk(L)x(Y)kz-nx, where the ligand L has the formula (I), and to metal complex compounds which include the reaction product of at least one salt or a complex of a transition metal or a main group metal element of the groups 13 to 15 and at least one 1,3-ketoamide. Such complex compounds are suitable in particular as catalysts for polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such metal complex compound as the catalyst. The invention additionally relates to different uses of the two-component polyurethane compositions.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: August 15, 2017
    Assignee: SIKA TECHNOLOGY AG
    Inventors: Urs Burckhardt, Rita Cannas
  • Patent number: 9642827
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 9, 2017
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9636320
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 2, 2017
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9610265
    Abstract: Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and/or fever.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: April 4, 2017
    Assignee: MALLINCKRODT IP
    Inventors: Mike Allan Royal, James Bradley Breitmeyer
  • Patent number: 9597531
    Abstract: Provided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction and treatment of body contour defects such as abdominal bulging; comprising an injectable formulation, said formulation comprising: an active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic long-acting selective beta-2 adrenergic receptor agonists, or salts, solvates, or polymorphs thereof; and one or more subcutaneously acceptable inactive ingredients.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: March 21, 2017
    Assignee: NEOTHETICS, INC.
    Inventors: John Daniel Dobak, Kenneth Walter Locke
  • Patent number: 9585962
    Abstract: A composition of cyclodextrin and colchicine in a dermatologically acceptable cream base provided improved clearance of actinic keratoses following topical application for 1 to 3 months. The composition provides improved clearance of recalcitrant actinic keratoses. Furthermore, the treatment causes much less pain and irritation than other topical treatments for actinic keratoses.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: March 7, 2017
    Inventor: Lawrence Moy
  • Patent number: 9504667
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: November 29, 2016
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9346746
    Abstract: The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: May 24, 2016
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Muhammad Safadi, Anton Frenkel, Michal Keisar, Danit Licht, Eliezer Bahar, Ramy Lidor-Hadas, Marina Zholkovsky, Rachel Cohen
  • Patent number: 9216303
    Abstract: Mascara primer and mascara formulations are disclosed.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: December 22, 2015
    Assignee: MARY KAY INC.
    Inventors: Greg Norman, Maria Milagros Sanchez
  • Patent number: 9211397
    Abstract: A patch for treatment of eyelid diseases that is provided with a support, a pressure-sensitive adhesive layer, and a release layer in this order, wherein (a) the pressure-sensitive adhesive layer includes the following (a-1) to (a-4): (a-1) a styrene-isoprene-styrene block copolymer, a tackifier resin, and a softening agent are contained; (a-2) a ratio (mass ratio) of the styrene-isoprene-styrene block copolymer and the tackifier resin is 1:2 to 1:4; (a-3) a content of the softening agent is 40% to 60% by mass; and (a-4) further 0.005% to 5% by mass of clobetasol or acid ester thereof is contained; and (b) the support has elastic modulus with a Young's modulus of 0.01 to 0.5 GPa: and a method for producing the patch for treatment of eyelid diseases including: forming a pressure-sensitive adhesive layer on a upper surface of a release layer.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 15, 2015
    Assignee: SENJU USA, INC.
    Inventors: Takahiro Ogawa, Akiharu Isowaki, Koji Kawahara, Takao Hiraoka, Mariko Tanaka, Chihiro Kenmochi
  • Publication number: 20150141518
    Abstract: A method to improve the stability of unstable drug substances in solution is described. Such solution compositions are water -miscible, can be refrigerated, sterilized and even co-administered with other pharmaceutical products without causing precipitation of the active ingredient. A particular example of such a stable, water-miscible solution composition for paracetamol is disclosed.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 21, 2015
    Inventors: Rebanta Bandyopadhyay, Susen Werle
  • Publication number: 20150140048
    Abstract: The invention relates to the use of N-methyl-N-C8-C14-acylglucamines as solubilizers in cosmetic preparations. The invention further relates to clear lotions for the preparation of wet wipes, comprising a) 0.1 to 5.0 wt.-% of the N-methyl-N—C8-C14-acylglucamines, b) 0.05 to 5% of one or more water-insoluble or only partially water-soluble anti-microbial agents, c) 0 to 5 wt.-% of one or more oils, d) 85 to 99.85 wt.-% of water, e) 0 to 5 wt.-% of surfactants, and f) 0 to 5 wt.-% of additional auxiliaries and additives.
    Type: Application
    Filed: May 29, 2013
    Publication date: May 21, 2015
    Applicant: CLARIANT FINANCE (BVI) LIMITED
    Inventors: Peter Klug, Carina Mildner
  • Patent number: 9034359
    Abstract: The present invention relates to a drug carrier composition comprising i) one or more biodegradable hydrating ceramics ii) one or more expandable agents, and iii) sorbed aqueous medium which in solid form has a ruptured structure. The function of the expandable agent is to create a ruptured structure in the solidified composition, either a foam-like structure or a disintegrated structure where it is split into a large number of parts, particles, units, granules or pieces, so as to obtain an enlarged apparent surface area that is exposed to degradation or erosion upon administration. Suitable substances to obtain this surface enlarging effect are gas-forming agents or swelling agents, gelling agents or disintegrants, here referred to as expandable agents. The expandable agents may be bioresorbable or non-bioresorbable.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 19, 2015
    Assignee: Lidds AB
    Inventors: Hans Lennernäs, Bo Lennernäs, Jonas Hugosson, Niklas Axén
  • Publication number: 20150126473
    Abstract: The present disclosure provides an isolated particle comprising very high density, ultra small, lipid depleted apo B containing particles, and may also contain cytokeratin 8. The isolated particle is useful in diagnostic assays, which are also provided.
    Type: Application
    Filed: June 14, 2012
    Publication date: May 7, 2015
    Applicant: Children's Hospital & Research Center at Oakland
    Inventors: Ronald M. Krauss, Mohmed Elfatih Ashmaig
  • Publication number: 20150126437
    Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.
    Type: Application
    Filed: October 17, 2012
    Publication date: May 7, 2015
    Applicant: The Regents of the University of California
    Inventors: Anandasankar Ray, Sean Michael Boyle
  • Publication number: 20150119468
    Abstract: Methods are provided herein for treating an individual having a disease, disorder or condition affecting the lungs, wherein said disease, disorder, or condition of the lung is an acute lung injury. In specific embodiments, the acute lung injury is chemical induced acute lung injury (CIALI). In some embodiments, the methods are provided for treating or protecting a subject from chemical induced acute lung injury that include administering to the subject a therapeutically effective amount of a phosphatase located on chromosome 10 (PTEN) inhibitor such as N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl)pivalamide (SF1670). In some embodiments, the method products a subject from CAILI or reduces CAILI that results from a subsequent exposure to a chemical that induces chemical induced acute lung injury.
    Type: Application
    Filed: October 23, 2014
    Publication date: April 30, 2015
    Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education
    Inventor: George Douglas Leikauf
  • Publication number: 20150111749
    Abstract: Methods and compositions for controlling plant pests, particularly weeds and/or plant phytopathogens using sarmentine and/or analogs thereof are disclosed.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 23, 2015
    Inventors: Huazhang Huang, Ratnakar Asolkar
  • Patent number: 9005660
    Abstract: The present invention relates to immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. In particular, this disclosure provides immediate release pharmaceutical compositions comprising a polyglycol having a molecular weight of from about 900 to about 17,000 daltons, a drug substance, one or more effervescent agents, and, optionally, one or more disintegrants, such that the composition is formulated to be resistant to abuse by intake of alcohol.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: April 14, 2015
    Assignee: Egalet Ltd.
    Inventors: Peter Holm Tygesen, Jan Martin Oevergaard, Joakim Oestman
  • Patent number: 9000046
    Abstract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: April 7, 2015
    Assignee: Depomed, Inc.
    Inventors: Bret Berner, Cuiping Chen
  • Patent number: 8999961
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 7, 2015
    Assignees: Purdue Pharma, L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 9000013
    Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: April 7, 2015
    Inventor: Alfred A. Nickel
  • Publication number: 20150094375
    Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Applicant: Hikma Pharmaceuticals LLC
    Inventor: Murray Ducharme
  • Publication number: 20150094322
    Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventor: Susanne Riel
  • Publication number: 20150094317
    Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Applicant: Hikma Pharmaceuticals LLC
    Inventor: Murray DUCHARME
  • Publication number: 20150094318
    Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Applicant: HIKMA PHARMACEUTICALS LLC
    Inventor: Murray Ducharme
  • Publication number: 20150094323
    Abstract: Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventor: Susanne Riel
  • Publication number: 20150087715
    Abstract: New polymorphic form of a long-acting beta-2 adrenoceptor agonist A new polymorphic form of arformoterol tartrate, designated as form D, is provided and which is characterised by at least one of the following: (i) a powder X-ray diffraction pattern having peaks at approximately 6.8, 13.3, 13.6, 3.8, 14.1, 18.2, 18.7, 20.0±0.2 degrees two theta; or (ii) a DSC thermogram showing an endothermic peak with an onset at approximately 19-120° C., and a maximum at approximately 129-131° C., followed by an exothermic peak with a maximum at approximately 137-138° C.; wherein the DSC thermogram of form D has a further endothermic peak with an onset at approximately 168-170° C.1 Processes for preparing the new polymorphic form, uses thereof and intermediates for the preparation thereof, are also provided.
    Type: Application
    Filed: March 12, 2013
    Publication date: March 26, 2015
    Applicant: LABORATORIOS LESVI S.L.
    Inventors: Jordi Benet-Buchholz, Jordi Cerón Bertran, Glòria Freixas Pascual, Pere Dalmases Barjoan, Isabel Navarro Muñoz
  • Patent number: 8987262
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: March 24, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Patent number: 8981150
    Abstract: Novel ether-amide compounds are described. Uses of the compounds, in particular as solvents, for example in phytosanitary formulations are also described.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: March 17, 2015
    Assignee: Rhodia Operations
    Inventors: Thierry Vidal, Massimo Guglieri, Olivier Jentzer
  • Publication number: 20150071864
    Abstract: A reversely thermo-reversible hydrogel composition comprising a water soluble block copolymer comprising at least two blocks of polyethylene oxide and at least one block of polypropylene oxide, and at least one associative gelling adjuvant having water solubility less than 0.5 g/100 ml, preferably less than 0.3 g/100 ml at 20° C., and being capable of forming water soluble inter-molecular complexes with the water soluble block copolymer in water. The hydrogel composition exhibits improved gelling efficiency, enhanced solubility and/or stability for water sparely soluble and insoluble pharmaceutical agents. The hydrogel compositions are useful in a variety of pharmaceutical and cosmetic products and applications, such as esophageal, otic, vaginal, rectal, ophthalmic, treatments of disorders and imperfections of the skin, and treating and/or preventing alopecia and restoring and/or promoting hair growth.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 12, 2015
    Applicant: Broda Technologies Co., Ltd.
    Inventors: Shao Xiang LU, Jeffrey LU, Letian LIU
  • Publication number: 20150057358
    Abstract: A sustained release dosage form comprises an active ingredient blended with a polymeric matrix. At least a portion of the polymeric matrix is formed by a cellulose ether having an onset dissolution temperature of at least 40° C., having anhydroglucose units joined by 1-4 linkages and having methyl groups, hydroxyalkyl groups, and optionally alkyl groups being different from methyl as substituents such that the cellulose ether has an MS (hydroxyalkyl) of 0.05 to 1.00, and hydroxyl groups of anhydrogluclose units are substituted with methyl groups such that [s23/s26?0.2*MS(hydroxyalkyl)] is 0.31 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 3-positions of the anhydroglucose unit are substituted with a methyl group and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxyl groups in the 2- and 6-positions of the anhydroglucose unit are substituted with a methyl group.
    Type: Application
    Filed: April 8, 2013
    Publication date: February 26, 2015
    Inventors: Meinolf Brackhagen, Roland Adden, Oliver Petermann, Robert L. Sammler, David E. Wallick
  • Publication number: 20150057359
    Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
    Type: Application
    Filed: October 10, 2014
    Publication date: February 26, 2015
    Applicant: HIKMA PHARMACEUTICALS LLC
    Inventor: Murray Ducharme
  • Publication number: 20150044297
    Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralised acid.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Inventors: Karim Ioualalen, Rose-Anne Raynal
  • Patent number: 8951541
    Abstract: Method of modifying dissolution rate of a plurality of particles in an aqueous-based solvent by adding hydrophobic surface modified nanoparticles to the plurality of particles, and exposing the plurality of particles to the aqueous-based solvent.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: February 10, 2015
    Assignee: 3M Innovative Properties Company
    Inventors: Jimmie R. Baran, Jr., Haeen Sykora, Rebecca L. A. Everman
  • Publication number: 20150038588
    Abstract: The invention provides a method of treating benzodiazepine-resistant status epilepticus in a subject having been exposed to a nerve agent inducing the status epilepticus.
    Type: Application
    Filed: March 6, 2013
    Publication date: February 5, 2015
    Inventors: Meir Bialer, Boris Yagen
  • Patent number: 8946295
    Abstract: A method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth factors in the early phase of wound healing, and suppressing fibrogenic cytokines/growth factors in the late phase of tissue remodeling in the wound site, and is useful in promoting epithelial cell re-growth and reducing excessive collagen accumulation, which results in rapid wound closure with reduced scaring.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: February 3, 2015
    Assignee: Sunny Pharmtech Inc.
    Inventor: Yih-Lin Chung